On May 4, 2021 Invectys Inc., a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, reported that Praveen Tyle, Ph.D., Invectys Inc. President and CEO, and Julien Caumartin, Ph.D. CSO of Invectys SA, will participate in the Roth Virtual Healthcare Private Company Forum, on Monday, June 28th, 2021 (Press release, Invectys, MAY 4, 2021, View Source [SID1234584362]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tyle will speak on the panel titled "Novel Approaches to Tumor Eradication" at 9:00am a.m. ET. Invectys, Inc focuses on a multi-modality approach to targeting HLA-G on tumor cells and also an approach with universal tumor antigen telomerase.